Solara Active Pharma Sciences Limited
The quarter and outlook are readable, but there's no valuation we'd stand behind — so this says nothing about what you'd pay.
Overall read
5.2/10
No price read
The three reads · this quarter
The quarter and outlook are readable, but there's no valuation we'd stand behind — so this says nothing about what you'd pay.
Overall read
5.2/10
No price read
The three reads · this quarter
The quarter and outlook are readable, but there's no valuation we'd stand behind — so this says nothing about what you'd pay.
Overall read
5.2/10
No price read
The three reads · this quarter
The standing reads · change less often
Moat
No moat read published yet.
Key variables
No key-variables snapshot yet.
Walk the talk
Not enough tracked guidance to grade yet.
Base business delivers 24% YoY growth in Q1 FY27 with ~26% EBITDA margin, showcasing strong momentum.
Latest · newest first
1w ago · Fundraising
Conversion of partly paid-up rights shares into fully paid-up upon receipt of call monies.
23 Jul 2026 · Fundraising
No deviation or variation of funds raised through Rights Issue for quarter ended June 30, 2026.
23 Jul 2026 · Business Update
Appointed Ajit Manocha as Chief Information Officer and designated as Senior Management.
23 Jul 2026 · Business Update
Solara reports strong Q1 FY27 base business performance with continued growth.
23 Jul 2026 · Business Update
Solara reports strong Q1 FY27 base business performance with continued growth.
Where it sits